Abstract
Early detection of Alzheimer’s disease (AD) has been a major focus of current research efforts to guide interventions at the earliest stages of the disease. Subtle changes to the brain might be observed with neuroimaging techniques, even before symptoms surface. We interrogated brain images obtained with Magnetic Resonance Imaging (MRI) from two large-scale dementia datasets (namely, ADNI and BioFIND) to establish the utility of fractal dimensionality (FD)—a relatively understudied measure that estimates the complexity of 3D structures (in this case, brain regions)—for the detection of AD. We show that FD can be used to detect group differences between patients and healthy controls, with the former showing significantly reduced complexity across multiple brain regions. Furthermore, these measures were successful when used as features for individual-based classification and were highly consistent across the two datasets. Finally, the contribution of specific brain regions to individual-based classification adhered to previous literature on the properties of the brain’s memory network. Taken together, the study offers novel and interpretable evidence for the utility of FD for the detection of AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Source ADNI data is available via ADNI project: https://adni.loni.usc.edu/, and source BioFIND data is available via DPUK portal: https://www.dementiasplatform.uk/.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Raw ADNI data is available via ADNI project: https://adni.loni.usc.edu/, and raw BioFIND data is available via DPUK portal: https://www.dementiasplatform.uk/. Preprocessed (derived) data used for group analyses, ML classification, trained models, and all code used throughout the study, are available through: https://github.com/ronitibon/FDAD.
